AAMU
XBIT icon

Amundi Asset Management US’s XBiotech XBIT Stock Holding History

Amundi Asset Management US’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15,694
Closed -$50K – 1670
2018
Q3 		$50K Hold
15,694
– – ﹤0.01% 1563
2018
Q2 		$70K Hold
15,694
– – ﹤0.01% 1489
2018
Q1 		$84K Buy
15,694
+800
+5% +$3.69K ﹤0.01% 1437
2017
Q4 		$59K Buy
+14,894
New +$62.7K ﹤0.01% 1481

Other funds holding XBIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Amundi Asset Management US's XBIT Position: Q4 2018 in Review

Amundi Asset Management US sold out of XBiotech (XBIT) in Q4 2018, closing a stake of 15,694 shares — an estimated $50K sold.

Amundi Asset Management US first reported a position in XBIT in Q4 2017 and held it in 4 quarters. The position peaked at $84K in Q1 2018. 25 funds tracked by Wall St. Rank hold XBIT as of Q4 2018.

  • Amundi Asset Management US reported no remaining XBiotech position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 15,694 XBiotech shares in Q4 2018, an estimated $50K.
  • Amundi Asset Management US first reported a position in XBiotech in Q4 2017 and held it in 4 quarters.
  • Amundi Asset Management US's XBiotech position peaked at $84K in Q1 2018.
  • 25 funds tracked by Wall St. Rank held XBiotech as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.